Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Mereo Biopharma Group Plc ( (MREO) ) is now available.
On July 9, 2025, Mereo BioPharma Group Plc and Ultragenyx Pharmaceutical Inc. announced that the Phase 3 Orbit study of UX143 (setrusumab) for osteogenesis imperfecta is progressing as planned, with final analysis expected by year-end. The Data Monitoring Committee confirmed the drug’s acceptable safety profile, allowing the study to continue, with final analyses to be conducted after 18 months of therapy.
The most recent analyst rating on (MREO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Mereo Biopharma Group Plc stock, see the MREO Stock Forecast page.
Spark’s Take on MREO Stock
According to Spark, TipRanks’ AI Analyst, MREO is a Neutral.
Mereo Biopharma Group’s overall stock score reflects significant financial and operational challenges typical of an early-stage biotech firm. The lack of revenue and ongoing cash flow issues weigh heavily on its financial performance. Technical indicators suggest some bearish momentum, although not excessively so. The valuation remains unattractive with a negative P/E ratio and no dividends, indicating limited immediate returns for investors.
To see Spark’s full report on MREO stock, click here.
More about Mereo Biopharma Group Plc
Mereo BioPharma Group Plc operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative therapeutics for rare diseases and oncology. The company collaborates with partners to advance its pipeline of product candidates.
Average Trading Volume: 1,420,296
Technical Sentiment Signal: Buy
Current Market Cap: $450M
For an in-depth examination of MREO stock, go to TipRanks’ Overview page.